// App-Quantinova.ai

88 : An Open-Label Proof-of-Principle Phase 2A Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)

Researchers

Presenter

  • A. Chruscinski

Principal Investigators

  • H. Atkins

  • A. Clement

  • D. Grant

  • C. Bredsen

  • E. Renner

  • J. Zhang

  • M. Epstein

  • L. Lilly

  • N. Selzner

  • O. Adeyi

  • R. Smith

  • S. Moshkelgosha

  • A. Humar

  • S. Juvet

  • G. Levy

Medical Centers

  • Multi-Organ Transplant, University Health Network, Toronto, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 34

  • Regulatory T cells

  • T-cell receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Everolimus

  • Busulfan

  • Allopurinol

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved